Fianlimab Plus Cemiplimab Induces High Clinical Activity Response for Patients With Advanced Melanoma
At the 2023 ASCO Annual Meeting, Omid Hamid, MD, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, shares results from a trial examining the combination treatment of fianlimab plus cemiplimab for patients with advanced melanoma.
This study found that fianlimab plus cemiplimab showed high clinical activity among patients with advanced melanoma. These data provide the first indication of that LAG-3 blockade demonstrates high activity with significant response rates among patients with advanced melanoma who have already recieved adjuvant anti-PD1 treatment.
Source:
Hamid O, Lewis KD, Weis AM. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, Illinois. Abstract 9501
